Generic Drug Repurposing in Canada

A Canadian Manufacturer’s Perspective

The COVID-19 pandemic has highlighted multiple and unprecedented challenges for the Canadian healthcare system, and the need for greater speed and flexibility in the provision of new therapeutic options for Canadians.

New therapeutic solutions do not necessarily require the full development of novel drugs or vaccines. There are multiple examples of significant therapeutic developments made possible by developing new indications or adapted formulations of existing agents to serve new patient populations. This process is known as “drug repurposing.”

Read our recommendations to encourage drug repurposing here